Lorena Baboci

List of Publications by Year in descending order

25 papers	717 citations	471509 17 h-index	610901 24 g-index
26 all docs	26 docs citations	26 times ranked	1571 citing authors

#	Article	IF	Citations
1	Radiation recall dermatitis induced by COVID-19 vaccination in breast cancer patients treated with postoperative radiation therapy. Breast, 2022, 65, 49-54.	2.2	7
2	Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 787864.	2.8	11
3	The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. Frontiers in Neuroscience, 2020, 14, 603647.	2.8	24
4	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702.	14.4	53
5	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. Journal of Oncology, 2020, 2020, 1-15.	1.3	33
6	Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy. Cell Death and Disease, 2020, 11, 392.	6.3	14
7	Abstract 1794: Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy. , 2020, , .		0
8	New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers, 2019, 11, 1086.	3.7	41
9	A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning. Cancers, 2019, 11, 1562.	3.7	31
10	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	3.1	28
11	Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing. PLoS ONE, 2018, 13, e0194619.	2.5	7
12	A 3â€year interval is too short for reâ€screening women testing negative for human papillomavirus: a populationâ€based cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1585-1593.	2.3	16
13	Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. European Journal of Cancer, 2017, 74, 73-81.	2.8	59
14	Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16â€driven oropharyngeal squamous cell carcinoma. International Journal of Cancer, 2017, 140, 2748-2757.	5.1	92
15	Multicenter research into the quality of life of patients with advanced oropharyngeal carcinoma with long-term survival associated with human papilloma virus. Oncology Letters, 2017, 14, 185-193.	1.8	8
16	Low prevalence of HPV-driven head and neck squamous cell carcinoma in North-East Italy. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 133-140.	4.5	30
17	Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. Cancer and Metastasis Reviews, 2016, 35, 457-474.	5.9	48
18	Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics, 2016, 11, 61-73.	2.7	29

#	Article	IF	Citations
19	Long-Term Clinical Outcome after Treatment for High-Grade Cervical Lesions: A Retrospective Monoinstitutional Cohort Study. BioMed Research International, 2015, 2015, 1-8.	1.9	19
20	Telomere shortening in mucosa surrounding the tumor: Biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 500-507.	1.5	35
21	Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. Journal of Medical Screening, 2014, 21, 30-37.	2.3	24
22	Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. Journal of Clinical Virology, 2014, 60, 257-263.	3.1	25
23	Use of a highâ€risk human papillomavirus <scp>DNA</scp> test as the primary test in a cervical cancer screening programme: a populationâ€based cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1260-1268.	2.3	47
24	Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virology Journal, 2013, 10, 334.	3.4	14
25	Oral Human Papillomavirus and Human Herpesvirus-8 Infections Among Human Immunodeficiency Virus Type 1â€“Infected Men and Women in Italy. Sexually Transmitted Diseases, 2012, 39, 894-898.	1.7	22